Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis

Elisabeth P. Dellon, Scott H. Donaldson, Robin Johnson, Stephanie Davis

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Inhaled hypertonic saline (HS) improves lung function and decreases pulmonary exacerbations in older patients with cystic fibrosis (CF) Initiating therapies in young patients has potential to preserve lung function. Before conducting a therapeutic trial of HS in this population, its safety must be evaluated and protocols for monitoring response must be tested. Methods: We administered single dose 3% and 7% HS post-albuterol to 4-7 year-olds with CF able to perform spirometry ("preschool" group) and 4 month to 3 year-olds ("infant" group) using the raised volume rapid thoracoabdominal compression technique (RVRTC). Vital signs and cough episodes were measured after each inhaled treatment. Results: Eight preschool subjects (mean age 5.7 ± 0.8 years) and 6 infants (1.6 ± 1.0 years) completed the 3% HS protocol, and no clinically important change in vital signs or decrease in FVC, FEV1, FEV0.5, or FEF25-75 occurred post-HS. Preschoolers had more cough episodes post-HS (P=0.01). Seven preschoolers (6.1 ± 0.7 years) and 8 infants (1.6 ± 0.7 years) completed the 7% HS protocol. In the preschool group, FVC, FEV0.5, and FEF25-75 did not change significantly. A statistically significant drop in median FEV1, occurred post-7% HS attributable to a transient >20% drop in one subject. Infant PFT parameters were unchanged post-7% HS. Preschoolers had more cough episodes post-HS (P=0.03). Conclusion: Acute administration of 3% and 7% HS appears to be safe and well-tolerated in most young children with CF Given the demonstrated benefits in older patients, a therapeutic trial in this age group is warranted. Pediatr Pulmonol. 2008; 43:1100-1106.

Original languageEnglish (US)
Pages (from-to)1100-1106
Number of pages7
JournalPediatric Pulmonology
Volume43
Issue number11
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Cystic Fibrosis
Cough
Safety
Vital Signs
Lung
Albuterol
Spirometry
Therapeutics
Age Groups
Population

Keywords

  • Child
  • Cystic fibrosis
  • Hypertonic saline solution
  • Safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. / Dellon, Elisabeth P.; Donaldson, Scott H.; Johnson, Robin; Davis, Stephanie.

In: Pediatric Pulmonology, Vol. 43, No. 11, 11.2008, p. 1100-1106.

Research output: Contribution to journalArticle

Dellon, Elisabeth P. ; Donaldson, Scott H. ; Johnson, Robin ; Davis, Stephanie. / Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. In: Pediatric Pulmonology. 2008 ; Vol. 43, No. 11. pp. 1100-1106.
@article{5bf1b8c5abb548d799f573941bacdd70,
title = "Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis",
abstract = "Background: Inhaled hypertonic saline (HS) improves lung function and decreases pulmonary exacerbations in older patients with cystic fibrosis (CF) Initiating therapies in young patients has potential to preserve lung function. Before conducting a therapeutic trial of HS in this population, its safety must be evaluated and protocols for monitoring response must be tested. Methods: We administered single dose 3{\%} and 7{\%} HS post-albuterol to 4-7 year-olds with CF able to perform spirometry ({"}preschool{"} group) and 4 month to 3 year-olds ({"}infant{"} group) using the raised volume rapid thoracoabdominal compression technique (RVRTC). Vital signs and cough episodes were measured after each inhaled treatment. Results: Eight preschool subjects (mean age 5.7 ± 0.8 years) and 6 infants (1.6 ± 1.0 years) completed the 3{\%} HS protocol, and no clinically important change in vital signs or decrease in FVC, FEV1, FEV0.5, or FEF25-75 occurred post-HS. Preschoolers had more cough episodes post-HS (P=0.01). Seven preschoolers (6.1 ± 0.7 years) and 8 infants (1.6 ± 0.7 years) completed the 7{\%} HS protocol. In the preschool group, FVC, FEV0.5, and FEF25-75 did not change significantly. A statistically significant drop in median FEV1, occurred post-7{\%} HS attributable to a transient >20{\%} drop in one subject. Infant PFT parameters were unchanged post-7{\%} HS. Preschoolers had more cough episodes post-HS (P=0.03). Conclusion: Acute administration of 3{\%} and 7{\%} HS appears to be safe and well-tolerated in most young children with CF Given the demonstrated benefits in older patients, a therapeutic trial in this age group is warranted. Pediatr Pulmonol. 2008; 43:1100-1106.",
keywords = "Child, Cystic fibrosis, Hypertonic saline solution, Safety",
author = "Dellon, {Elisabeth P.} and Donaldson, {Scott H.} and Robin Johnson and Stephanie Davis",
year = "2008",
month = "11",
doi = "10.1002/ppul.20909",
language = "English (US)",
volume = "43",
pages = "1100--1106",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis

AU - Dellon, Elisabeth P.

AU - Donaldson, Scott H.

AU - Johnson, Robin

AU - Davis, Stephanie

PY - 2008/11

Y1 - 2008/11

N2 - Background: Inhaled hypertonic saline (HS) improves lung function and decreases pulmonary exacerbations in older patients with cystic fibrosis (CF) Initiating therapies in young patients has potential to preserve lung function. Before conducting a therapeutic trial of HS in this population, its safety must be evaluated and protocols for monitoring response must be tested. Methods: We administered single dose 3% and 7% HS post-albuterol to 4-7 year-olds with CF able to perform spirometry ("preschool" group) and 4 month to 3 year-olds ("infant" group) using the raised volume rapid thoracoabdominal compression technique (RVRTC). Vital signs and cough episodes were measured after each inhaled treatment. Results: Eight preschool subjects (mean age 5.7 ± 0.8 years) and 6 infants (1.6 ± 1.0 years) completed the 3% HS protocol, and no clinically important change in vital signs or decrease in FVC, FEV1, FEV0.5, or FEF25-75 occurred post-HS. Preschoolers had more cough episodes post-HS (P=0.01). Seven preschoolers (6.1 ± 0.7 years) and 8 infants (1.6 ± 0.7 years) completed the 7% HS protocol. In the preschool group, FVC, FEV0.5, and FEF25-75 did not change significantly. A statistically significant drop in median FEV1, occurred post-7% HS attributable to a transient >20% drop in one subject. Infant PFT parameters were unchanged post-7% HS. Preschoolers had more cough episodes post-HS (P=0.03). Conclusion: Acute administration of 3% and 7% HS appears to be safe and well-tolerated in most young children with CF Given the demonstrated benefits in older patients, a therapeutic trial in this age group is warranted. Pediatr Pulmonol. 2008; 43:1100-1106.

AB - Background: Inhaled hypertonic saline (HS) improves lung function and decreases pulmonary exacerbations in older patients with cystic fibrosis (CF) Initiating therapies in young patients has potential to preserve lung function. Before conducting a therapeutic trial of HS in this population, its safety must be evaluated and protocols for monitoring response must be tested. Methods: We administered single dose 3% and 7% HS post-albuterol to 4-7 year-olds with CF able to perform spirometry ("preschool" group) and 4 month to 3 year-olds ("infant" group) using the raised volume rapid thoracoabdominal compression technique (RVRTC). Vital signs and cough episodes were measured after each inhaled treatment. Results: Eight preschool subjects (mean age 5.7 ± 0.8 years) and 6 infants (1.6 ± 1.0 years) completed the 3% HS protocol, and no clinically important change in vital signs or decrease in FVC, FEV1, FEV0.5, or FEF25-75 occurred post-HS. Preschoolers had more cough episodes post-HS (P=0.01). Seven preschoolers (6.1 ± 0.7 years) and 8 infants (1.6 ± 0.7 years) completed the 7% HS protocol. In the preschool group, FVC, FEV0.5, and FEF25-75 did not change significantly. A statistically significant drop in median FEV1, occurred post-7% HS attributable to a transient >20% drop in one subject. Infant PFT parameters were unchanged post-7% HS. Preschoolers had more cough episodes post-HS (P=0.03). Conclusion: Acute administration of 3% and 7% HS appears to be safe and well-tolerated in most young children with CF Given the demonstrated benefits in older patients, a therapeutic trial in this age group is warranted. Pediatr Pulmonol. 2008; 43:1100-1106.

KW - Child

KW - Cystic fibrosis

KW - Hypertonic saline solution

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=57349158832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349158832&partnerID=8YFLogxK

U2 - 10.1002/ppul.20909

DO - 10.1002/ppul.20909

M3 - Article

C2 - 18828160

AN - SCOPUS:57349158832

VL - 43

SP - 1100

EP - 1106

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 11

ER -